GW9662, an inhibitor of PPARG26, it was able to inhibit key genes involved in fatty acid metabolism (Supplementary figure 5A), and it reduced the accumulation of fatty acids in HER2-positive breast cancer cells (Figure 7A). Here, ERBB2 is linked to breast carcinoma.